COMMUNIQUÉS West-GlobeNewswire
-
J-Star Signs MOU with PSSB to Provide Resins for Batteries
14/01/2026 -
Cannara obtient la qualification OTCQX et annonce la publication de ses résultats financiers du premier trimestre de l'exercice 2026 le 26 janvier 2026
14/01/2026 -
Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026
14/01/2026 -
Counslr Expands Long Island Footprint to Support Mental Health in the New Year
14/01/2026 -
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
14/01/2026 -
Aeroflow Health and Blue Cross Complete of Michigan Partner to Deliver Essential DME to Medicaid Members
14/01/2026 -
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
14/01/2026 -
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
14/01/2026 -
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
14/01/2026 -
Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion
14/01/2026 -
Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results
14/01/2026 -
Human Appeal Concludes First-Ever U.S. Winter Coat Drive
14/01/2026 -
Verano Strengthens National Product Portfolio in Industry’s Fastest-Growing Category with Launch of Swift Lifts as Standalone Pre-roll Brand
14/01/2026 -
RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
14/01/2026 -
De nouvelles données renforcent l’engagement d’Ipsen à proposer des solutions et à combler les lacunes de prise en charge dans les maladies neurologiques lors du congrès TOXINS
14/01/2026 -
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
14/01/2026 -
Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future
14/01/2026 -
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
14/01/2026 -
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
14/01/2026
Pages